Skip to content ↓
Press Room

Federal Easing of Buprenorphine Restrictions Empowers Healthcare Providers With Important Tool for Preventing Overdose

The Biden administration is easing some of the two-decade old restrictions that made it difficult for providers to prescribe buprenorphine, a gold standard medication used to treat dependence in people suffering from opioid use disorder. 

Statement from Daliah Heller, Director of Drug Use Initiatives at Vital Strategies: 

About Vital Strategies  

Vital Strategies is a global health organization that believes every person should be protected by a strong public health system. We work with governments and civil society in 73 countries to design and implement evidence-based strategies that tackle their most pressing public health problems. Our goal is to see governments adopt promising interventions at scale as rapidly as possible. 

To find out more, please visit www.vitalstrategies.org or Twitter @VitalStrat

About Vital Strategies’ Overdose Prevention Program 

In November 2018, Bloomberg Philanthropies announced a $50 million investment to address the country’s overdose crisis. The initiative—a first-of-its-kind partnership between Vital Strategies, Pew Charitable Trusts, CDC Foundation, and Johns Hopkins Bloomberg School of Public Health—is helping up to 10 states implement solutions over three years to strengthen and scale up evidence-based, data-driven interventions to reduce risks of overdose and save lives.